



Europass Curriculum Vitae

Personal information

First name(s) / Surname(s)	Francesca Fazio
Address(es)	Division of Hematology, Department of Translational and Precision Medicine, Policlinico Umberto I – “Sapienza” University, Rome Via Benevento 6, 00161 Rome
Telephone(s)	
E-mail	
Nationality	Italian
Date of birth	
Gender	Female

Education and training

Dates	July 2004
Title of qualification awarded	High School Diploma in scientific studies
Principal subjects/occupational skills covered	Final grade of 92/100
Name and type of organisation providing education and training	Liceo Scientifico statale "A. Volta", Guardiaagrele, via Grele, 24/b - 66016

Dates	July 2014
Title of qualification awarded	Medical Degree
Principal subjects/occupational skills covered	Final grade of 110/110 with honors
Name and type of organisation providing education and training	Università "G. D'Annunzio" CHIETI-PESCARA
Dates	November 2015 - March 2016
Title of qualification awarded	Resident in Hematology
Principal subjects/occupational skills covered	Cell Blood count and Cytomorphology Laboratory, Flow Cytometry Laboratory, Molecular Biology Laboratory
Name and type of organization providing	Division of Hematology, Policlinico Umberto I - University "La Sapienza", Rome Via Benevento 6, 00161 Roma
Dates	March 2016 – May 2017
Title of qualification awarded	Resident in Hematology
Principal subjects/occupational skills covered	Management of haematological diseases: followed patients treated with experimental drug Blinatumomab, pre-transplant screening and complications of pediatric patients undergoing allergenic transplant, followed pediatric patients with bone marrow aplasia, thrombocytopenia and haemolytic anemia.
Name and type of organisation providing education and training	Department of Pediatric Hematology
Dates	May 2017 – November 2017
Title of qualification awarded	Resident in Hematology
Principal subjects/occupational skills covered	Diagnostic and therapeutic framework of patients with haematological pathologies and management of emergencies.
Name and type of organisation providing education and training	Hematological Emergency Room
Dates	November 2017 - May 2018
Title of qualification awarded	Resident in Hematology
Principal subjects/occupational skills covered	Diagnostic and therapeutic framework of patients with plasma cell dyscrasias and experimental protocol management.
Name and type of organisation providing education and training	University of Rome "Sapienza"
Dates	May 2018 – November 2018
Title of qualification awarded	Resident in Hematology
Principal subjects/occupational skills covered	

Name and type of organisation providing education and training	Diagnostic and therapeutic framework of patients with non-Hodgkin lymphoma, Hodgkin's lymphoma and experimental protocol management. University of Rome "Sapienza"
Dates	
Title of qualification awarded	
Principal subjects/occupational skills covered	November 2018 – May 2019 Resident in Hematology
Name and type of organisation providing education and training	Diagnostic and therapeutic framework of patients with systemic amyloidosis. IRCCS Foundation Policlinico San Matteo Pavia

Personal skills and competences

Dates	May 2019 – August 2019
Title of qualification awarded	Resident in Hematology
Principal subjects/occupational skills covered	Diagnostic and therapeutic framework of patients with thrombotic and hemorrhagic coagulopathies, autoimmune thrombocytopenia and essential thrombocythemias.
Name and type of organisation providing education and training	University of Rome “Sapienza”
Dates	August 2019 – October 2019
Title of qualification awarded	Resident in Hematology
Principal subjects/occupational skills covered	Diagnostic and therapeutic framework of patients with chronic and acute myeloproliferative diseases and myelodysplastic syndromes.
Name and type of organisation providing education and training	University of Rome “Sapienza”
Dates	November 2019
Title of qualification awarded	Specialization in Hematology [MED/15]
Principal subjects/occupational skills covered	Final grade of 70/70 with honors
Name and type of organisation providing education and training	University of Rome “Sapienza”
Dates	March 2023
Title of qualification awarded	PhD in “Innovation in Immuno-mediated and haematological disorders”. Project: “Next-generation sequencing of immunoglobulin genes: toward personalized medicine in AL amyloidosis
Name and type of organisation providing education and training	University of Rome “Sapienza”
Dates	November 2019 – present
Title of qualification awarded	Research grant at Department of Translational and Precision Medicine [MED/15]
Name and type of organisation providing education and training	Sapienza University of Rome
Dates	October 2019 – June 2020
Title of qualification awarded	Master di I livello in Management of Multiple Myeloma
Name and type of organisation providing education and training	European Myeloma Network Research Italy - Torino

Name and type of organisation providing education and training	June 2021 – July 2021 NGS School
Dates	Invivoscrib - Werfen
Title of qualification awarded	
Name and type of organisation providing education and training	
Prize and grants	Winner of grant for research in the field of systemic amyloidosis promoted by the Italian Society for Amyloidosis ONLUS (October 2018)
Personal skills and competences	
Mother tongue(s)	Italian
Other language(s)	Excellent knowledge of English language
Computer skills and competences	Good knowledge to of Microsoft Office™ (Word™, Excel™ and PowerPoint™) and basic knowledge of SPSS

Publications

1. Decreased plasma endogenous soluble RAGE, and enhanced adipokine secretion, oxidative stress and platelet/coagulative activation identify non-alcoholic fatty liver disease among patients with familial combined hyperlipidemia and/or metabolic syndrome. F. Santilli, P. Blardi, C. Scapellato, M. Bocchia, G. Guazzi, L. Terzuoli, A. Tabucchi, A. Silviotti, B. Lucani, W. Renato Giofrè, F. Scarpini, **F. Fazio**, G. Davì, L. Puccetti. *Vascul Pharmacol* 2015 Sep;72:16-24.
2. Response to Interferon-Free Direct Antivirals (DAAS) Treatment in Hcv-Related Subcutaneous Marginal Zone B-Cell Lymphoma with Lipoma-Like Presentation: Report of Two Cases. ML De Luca, L. Lombardi, G. Tartaglia, **F. Fazio**, A. Di Prima, A. Serrao, M. Canichella, A. Pulsoni. *Mediterr J Hematol Infect Dis* 2019 Sep 1;11(1):e2019053.
3. Efficacy of imatinib and chemotherapy in a pediatric patient with Philadelphia-like acute lymphoblastic leukemia with Ebf1-Pdgrfb fusion transcript. **F. Fazio**, W. Barberi, G. Cazzaniga, G. Fazio, M. Messina, I. Della Starza, MS De Propriis, F. Mancini, S. Mohamed, I. Del Giudice, S. Chiaretti, ML Moleti, A. Guarini, R. Foà, AM Testi. *Leuk Lymphoma* 2020 Feb;61(2):469-472.
4. High rate of profound clonal and renal responses with daratumumab treatment in heavily pre-treated patients with light chain (AL) amyloidosis and high bone marrow plasma cell infiltrate. P. Milani, **F. Fazio**, M. Basset, T. Berno, A. Larocca, A. Foli, M. Riva, F. Benigna, S. Oliva, M. Nuvolone, L. Rodigari, MT Petrucci, G. Merlini, G. Palladini. *A J Hematol* 2020 Aug;95(8):900-905.

5. Balanced and unbalanced chromosomal translocations in myelodysplastic syndromes: clinical and prognostic significance. S. Mohamed, R. Latagliata, M. Z. Limongi, S. Nigro, E. Sangiorgi, M. Nanni, A. Piccioni, A. Campagna, M. A. Aloe Spiriti, I. Carmosino, M. Molica, E. Marigliò, S. Rosati, G. Colafigli, **F. Fazio**, M. L. De Luca, D. De Benedittis, E. Scalzulli, M. Breccia, M. Mancini. *Leuk Lymphoma*. 2020 Dec;61(14):3476-3483.
6. Monoclonal antibodies in multiple myeloma. F. Vozella, **F. Fazio**, G. Lapietra, MT. Petrucci, G. Martinelli, C. Cerchione. *Panminerva Med*. 2021 Mar;63(1):21-27.
7. Monoclonal Antibodies: Leading Actors in the Relapsed/Refractory Multiple Myeloma Treatment. S. Morè, MT. Petrucci, L. Corvatta, **F. Fazio**, M. Offidani, A. Olivieri. *Pharmaceuticals (Basel)*. 2020 Nov 27;13(12):426.
8. Acquired FXIII deficiency and AL amyloidosis: A case of a rare association. A. Ferretti, E. Baldacci, **F. Fazio**, R. Abbruzzese, F. Barone, ML. De Luca, MT. Petrucci, A. Chistolini, MG. Mazzucconi, C. Santoro. *Transfus Apher Sci* 2020 Dec;59(6):102903
9. Posterior reversible encephalopathy syndrome (PRES) as complication in a patient with relapsed/refractory multiple myeloma. G. Lapietra, **F. Fazio**, F. Vozella, F. Pirolli, M.T. Petrucci. *Journal of Case Reports* 2020; 10(3):201-204.
10. Daratumumab before and after haploidentical hematopoietic stem cell transplantation in relapsed/refractory multiple myeloma: is the right strategy to overcome microenvironment impact in multiple myeloma? **F. Fazio**, L. Quattrocchi, L. Fiori, G. Lapietra and M. T. Petrucci. *J Clin Trials Res*, 3(3):211-214.
11. Venous thromboembolism prophylaxis in patients with multiple myeloma: where are we and where are we going? G. Lapietra, A. Serrao, **F. Fazio**, M. T. Petrucci, A. Chistolini. *J Thromb Thrombolysis*. 2021 Aug;52(2):584-589.
12. The Modern Age of Monoclonal Antibodies: The Revolution of Daratumumab. G. Lapietra, **F. Fazio**, MT Petrucci. Chapter in *Intechopen* 2021. G.
13. The unclear role of VEGF in the POEMS syndrome: therapeutic implications of neoangiogenesis in a rare plasma cell disorder. G. Lapietra, **F. Fazio**, MT Petrucci. *J Cancer Metastasis Treat* 2021;7 doi.org/10.20517/2394-184722.2021.106.
14. New Dead/H-Box Helicase Gene (Ddx41) mutation in an Italian family with recurrent leukemia. **F. Fazio**, M. Quintini, I. Carmosino, C. Matteucci, E. Miulli, F. Pellanera, B. Lucani, M. Ansuinelli, M. Breccia, C. Mecucci, R. Latagliata. *Leuk Lymphoma*. 2021 Sep;62(9):2280-2283
15. Impact on NK cell functions of acute versus chronic exposure to extracellular vesicle-associated MICA: Dual role in cancer immunosurveillance. E. Vulpis, L. Loconte, A. Peri, R. Molfetta, G. Caracciolo, L. Masuelli, L. Tomaipitca, G. Peruzzi, S. Petillo, MT Petrucci, **F. Fazio**, L. Simonelli, C. Fionda, A. Soriani, C. Cerboni, M. Cippitelli, R. Paolini, G. Bernardini, G. Palmieri, A. Santoni, A. Zingoni. *J Extracell Vesicles* 2022 Jan;11(1):e12176.

16. Blast morphology in the diagnostic work-up of Ph-like acute lymphoblastic leukemia. **F. Fazio**, G. Cunsolo, F. Mancini, A. Piciocchi, V. Arena, M. Messina, M. Ansuinelli, A. Taherinasab, V. Apicella, A. Vitale, S. Chiaretti, A. Guarini, I. Del Giudice, R. Foà. *Leuk Lymphoma* 2022 Feb 8:1-3.

17. Physicians' Perceptions of Clinical Utility of a Digital Health Tool for Electronic Patient-Reported Outcome Monitoring in Real-Life Hematology Practice. Evidence from the GIMEMA-ALLIANCE Platform. F. Efficace, A. Patriarca, M. Luppi, L. Potenza, G. Caocci, A. Tafuri, **F. Fazio**, C. Cartoni, M. T. Petrucci, I. Carmosino, R. Moia, G. Margiotta Casaluci, P. Boggione, El. Colaci, D. Giusti, V. Pioli, F. Sparano, F. Cottone, P. De Fabritiis, N. Rita Ardu, P. Niscola, I. Capodanno, A. P. Leporace, S. Pelliccia, E. Lugli, E. La Sala, L. Rigacci, M. Santopietro, C. Fozza, S. Siragusa, M. Breccia, P. Fazi and M. Vignetti. *Front Oncol.* 2022 Mar 17;12:826040.

18. An N-glycosylation hotspot in immunoglobulin κ light chains is associated with AL amyloidosis. Alice Nevone, Maria Girelli, Silvia Mangiacavalli, Bruno Paiva, Paolo Milani, Pasquale Cascino, Maggie Piscitelli, Valentina Speranzini, Claudio Salvatore Cartia, Pietro Benvenuti, Ibai Goicoechea, **Francesca Fazio**, Marco Basset, Andrea Foli, Martina Nanci, Giulia Mazzini, Serena Caminito, Melania Antonietta Sesta, Simona Casarini, Paola Rognoni, Francesca Lavatelli, Maria Teresa Petrucci, Pier Paolo Olimpieri, Stefano Ricagno, Luca Arcaini, Giampaolo Merlini, Giovanni Palladini and Mario Nuvolone. *Leukemia* (2022)

19. Auto-SCT in Multiple Myeloma patients over 70 years: a GIMEMA Lazio Working Group experience in a retrospective case-control study. A Rago, O Annibali, Tomarchio V, Coppetelli U, **F. Fazio**, Cupelli L, A Fiorini, Piciocchi A, Tafuri A, T Caravita di Toritto. *Eur J Haematol.* 2022 May 26

20. High levels of circulating plasma cells as a key hallmark of aggressive disease in transplant-eligible patients with newly diagnosed multiple myeloma. L. Bertamini, S. Oliva, D. Rota-Scalabrini, G. Galli, M. Offidani, P. Corradini, A. Ledda, M. Gentile, G. De Sabbata, G. Pietrantuono, R. Bassan, P. Tosi, M. Gilestro, A. Capra, P. Galieni, F. Pisani, O. Annibali, F. Monaco F, MA. Liberati, S. Palmieri, F. Narni, R. Zambello, **F. Fazio**, A. Belotti, P. Tachetti, P. Musto, M. Boccadoro. *J Clin Oncol.* 2022 Jun 6:JCO2101393. doi: 10.1200/JCO.21.01393

21. Daratumumab combined with dexamethasone and lenalidomide or bortezomib in relapsed/refractory multiple myeloma (RRMM) patients: report from the Multiple Myeloma Gimema Lazio Group. **F. Fazio**, L. Franceschini, V. Tomarchio, A. Rago, MG. Garzia. L. Cupelli, V. Bongarzoni, A. Andriani, S. Gumenyku, A. Tafuri, A. Siniscalchi, A. Piciocchi, P. De Fabritiis, L. De Rosa, T. Caravita, O. Annibali, M. Cantonetti, MT. Petrucci. *eJHaem* 2022;3:121-128.

22. GAS6/TAM signaling pathway controls MICA expression in multiple myeloma cells. Kosta A, Mekhloufi A, Lucantonio L, Zingoni A, Soriani A, Cippitelli M, Gismondi A, **Fazio F**, Petrucci MT, Santoni A, Stabile H, Fionda C. *Front Immunol.* 2022 Jul 28;13:942640.

23. Single-Molecule Real-Time Sequencing of the M protein: toward personalized medicine in monoclonal gammopathies. P. Cascino, A. Nevone, M. Piscitelli, C. Scopelliti, M. Girelli, G. Mazzini, S. Caminito, G. Russo, P. Milani, M. Basset, A. Foli, **F. Fazio**, S. Cascarini, M. Massa, M. Bozzola, J. Ripepi, M. Antonietta, G. Acquafredda, M. De Cicco, A. Moretta, P. Rognoni, E. Milano, S. Ricagno, F. Lvatelli, MT Petrucci, E. Miho, C. Klersy, G. Merlini, G. Palladini, M. Nuvolone. *Am J Hematol.* 2022 Nov;97(11):E389-E392.

24. Race for the Cure: From the Oldest to the Newest Monoclonal Antibodies for Multiple Myeloma Treatment. Lapietra G, **Fazio F**, Petrucci MT *Biomolecules.* 2022 Aug 19;12(8):1146.

25. Lenalidomide-based triplet regimens in first relapsed multiple myeloma patients: real-world evidence from a propensity score matched analysis. Mangiacavalli S, Cartia CS, Galli M, Pezzatti S, Belotti A, **Fazio F**, Mina R, Marcatti M, Cafro A, Zambello R, Paris L, Barilà G, Olivares C, Pompa A, Mazza R, Farina F, Soldarini M, Benvenuti P, Pagani G, Palumbo M, Masoni V, Ferretti VV, Klersy C, Arcaini L, Petrucci MT. Haematologica. 2022 Oct 6.

26. Immunogenicity of SARS-CoV-2 vaccination in patients undergoing autologous stem cell transplantation. A multicentric experience. Autore F, Stirparo L, Innocenti I, Papa E, Marchesi F, Togni C, Mariani S, Torrieri L, Salvatori M, **Fazio F**, Metafuni E, Giammarco S, Sora F, Falcucci P, Ferrari A, Trisolini SM, Capria S, Tafuri A, Chiusolo P, Sica S, Laurenti L. Front Oncol. 2022 Dec 2;12:897937.

27. Passucci M, **Fazio F**, Petrucci MT. A Case of Fatal Hyperammonaemic Encephalopathy in a Patient with End-Stage Multiple Myeloma. Mediterr J Hematol Infect Dis. 2023 Jan 1;15(1):e2023012.

I hereby authorize the use of sensitive data according do DL n.196 June 30, 2003.

Roma, 17.03.2023